Physicochemical Properties
Molecular Formula | C7H12N3NAO7S |
Molecular Weight | 305.240851402283 |
Exact Mass | 305.029 |
CAS # | 2938989-90-1 |
Related CAS # | Avibactam free acid;1192500-31-4;Avibactam sodium;1192491-61-4;Avibactam sodium dihydrate |
PubChem CID | 118704750 |
Appearance | White to off-white solid powder |
LogP | 0 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 3 |
Heavy Atom Count | 19 |
Complexity | 462 |
Defined Atom Stereocenter Count | 2 |
SMILES | C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)[O-])C(=O)N.O.[Na+] |
InChi Key | QTECZIOYYRSGNA-CIFXRNLBSA-M |
InChi Code | InChI=1S/C7H11N3O6S.Na.H2O/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15;;/h4-5H,1-3H2,(H2,8,11)(H,13,14,15);;1H2/q;+1;/p-1/t4-,5+;;/m1../s1 |
Chemical Name | sodium;[(2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] sulfate;hydrate |
HS Tariff Code | 2934.99.9001 |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
Targets | IC50: 5 nM (CTX-M-15), 8 nM (TEM-1)[1] |
ln Vitro | Avibactam is a compound with minimal antibacterial action that inhibits Acinetobacter OXA carbapenemases and class A and C β-lactamases, but not metallo types[2]. With MIC50 and MIC90 for both 8 mg/L, ceftazidime (HY-B0593)-avibactam (0-256 mg/L) suppresses the growth of 16 blaKPC -2 positive and 1 blaOXA-232 positive Klebsiella pneumonia[4]. |
ln Vivo | Ceftazidime-Avibactam (0.375 mg/g; sc; q8h for 10 days) significantly affects the bacteria and has been shown to have some therapeutic activity in an infected animal model with K. pneumoniae strain Y8[3]. In neutropenic mice infected with Pseudomonas aeruginosa and suffering from lung infection, avibactam (64 mg/kg; sc; once) has a mean estimated half-life in plasma in the terminal phase of 0.24 h[3]. |
Animal Protocol |
Animal/Disease Models: Sixweeks old balb/c (Bagg ALBino) mouse: (female), K. pneumoniae strain Y8 infection model[4] Doses: 0.375 mg/g in combination with Ceftazidime Route of Administration: subcutaneous (sc)injection, 4 h post infection and given every 8 h for 10 days Experimental Results: 70% of infection group mice died within 4 days, and all mice in the PBS group died within 13 days. All treatment group mice survived at 10 days post infection with the antibiotic applied every 8 h, whereas 100% of mice in this group died within 4 days after the antibiotic treatment stopped. The spleen and liver of treatment group mice demonstrated lower CFU counts, as compared with that of infected group. |
References |
[1]. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11663-8. [2]. Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104). J Antimicrob Chemother. 2012 Jun;67(6):1354-8. [3]. Pharmacokinetics and penetration of GR20263 and avibactam into epithelial lining fluid in thigh- and lung-infected mice. Antimicrob Agents Chemother. 2015 Apr;59(4):2299-304. [4]. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Klebsiella pneumoniae. Antimicrob Resist Infect Control. 2018 Nov 21;7:142. |
Solubility Data
Solubility (In Vitro) | H2O : ≥ 200 mg/mL (655.22 mM) |
Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (81.90 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.2761 mL | 16.3806 mL | 32.7611 mL | |
5 mM | 0.6552 mL | 3.2761 mL | 6.5522 mL | |
10 mM | 0.3276 mL | 1.6381 mL | 3.2761 mL |